KYORIN Pharmaceutical Co., Ltd. (4569) Stock Price

Kyorin Pharmaceutical is a company primarily engaged in the pharmaceutical business. The Kyorin Pharmaceutical Group consists of four companies in total: Kyorin Pharmaceutical, two subsidiary companies, and one affiliated company. The main business activity is the manufacture and sale of pharmaceutical products.

Kyorin Pharmaceutical manufactures and sells pharmaceutical products, with some raw materials sourced from its affiliated company, Nippon Rika Kagaku Yakuhin. Additionally, Kyorin Remedio also engages in the manufacture and sale of pharmaceutical products.

Furthermore, Kyorin Pharmaceutical Group Factory handles the manufacturing and testing of pharmaceutical products. Through these operations, the Kyorin Pharmaceutical Group has established an integrated system that covers pharmaceutical manufacturing through to sales.

Kyorin Pharmaceutical's corporate philosophy is to "cherish life and contribute to people's health." To realize this philosophy, the company has established "Vision 110," a long-term vision toward its 110th anniversary. This vision aims to contribute broadly to people's health by providing new drugs that address medical needs as its core business, while expanding health-related operations.

In 2023, marking its 100th anniversary, Kyorin Pharmaceutical launched "Vision 110–Stage 1–," a medium-term management plan representing the first phase of Vision 110. Covering the three-year period from fiscal 2023 to fiscal 2025, this plan aims to transform the company's business structure. Specifically, it pursues five business strategies to achieve performance targets.

Kyorin Pharmaceutical's growth strategy includes strengthening new drug discovery capabilities, expanding its development pipeline, and maximizing the ratio of new drugs. Also critical are promoting health-related businesses that create synergies with pharmaceutical operations and building a sustainable corporate foundation. Through these strategies, the company aims to provide high-value new drugs that address medical needs.

As progress on the medium-term plan, Kyorin Pharmaceutical has narrowed its drug discovery research focus to pulmonary fibrosis, pain, and autoimmune diseases. It is also strengthening its drug discovery platform through external technology partnerships and pursuing drug discovery innovation to create new value. This enables the development of high-value new drugs.

Furthermore, to expand its pipeline, Kyorin Pharmaceutical has established a new Business Development Division to accelerate the evaluation and acquisition of in-licensed products. In fiscal 2024, it has entered into license agreements with companies including Bayer and Biodol to advance development of new therapeutic drug candidates. This supports further pipeline expansion.

To maximize new drug adoption, the company is strengthening sales capabilities through digital promotion. It aims to increase sales of flagship products and maximize the new drug ratio. In fiscal 2025, it will focus on accelerating growth of five new drugs to drive new drug adoption.

To improve cost competitiveness, the company is pursuing cost reduction across all divisions while advancing human resource development and workplace reforms. It is also actively addressing environmental, compliance, and corporate governance matters to build a sustainable corporate foundation.